- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05162846
Methods for Increasing Genetic Testing Uptake in Michigan (MiGHT)
Study Overview
Status
Conditions
Detailed Description
This trial will be conducted in partnership with the Michigan Department of Health and Human Services (MDHHS) and a network of oncology practices in Michigan, the Michigan Oncology Quality Consortium (MOQC).
As of April 2023 we were approved by our IRB to expand our inclusion criteria and recruitment cohort. This expansion will enhance our reach to individuals who are not in the acute stages of clinical care as well as individuals who are not in oncology care currently yet still qualify for genetic testing based on their family history of cancer alone or in combination with any personal cancer history. These expansions will also support the unburdening of oncology practices - who continue to face downstream, resource-limiting affects from the COVID-19 pandemic - across the state. The goal and aims of the study remain the same.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Rogel Cancer Center
-
Contact:
- Cancer AnswerLine
- Phone Number: 800-865-1125
- Email: CancerAnswerLine@med.umich.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to speak and read English
- Access to the internet
- Completed the Family Health History Tool (FHHT) through the Michigan Oncology Quality Consortium (MOQC).
Meeting clinical criteria for genetic evaluation due to any of the below:
Personal history of Breast cancer either:
- i. Diagnosed under 50
- ii. Personal or family history of triple negative breast cancer
- iii. Ashkenazi Jewish ancestry
- iv. Male proband
- v. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
Personal history of prostate cancer either:
- i. Diagnosed under 50
- ii. Ashkenazi Jewish ancestry
- iii. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
Personal history of any cancer or no personal history of cancer with either:
- i. PREMM risk model score ≥ 2.5%
- ii. 1st degree relative with pancreatic, or male breast cancer
- iii. 1st or 2nd degree relative with ovarian cancer
- iv. 1st or 2nd degree relative with any of these cancers diagnosed under 50: colon, endometrial, or breast
- v. Ashkenazi Jewish ancestry and 1st or 2nd degree relative with breast cancer
- Personal history of edometrial cancer diagnosed under 50
- Personal history of colorectal cancer diagnosed under 50
- Personal history of ovarian cancer
- Personal history of pancreatic cancer
Exclusion Criteria:
- Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1 - Usual care (UC)
Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
|
Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
|
Experimental: Arm 2 - Virtual genetics navigator
Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
|
A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
|
Experimental: Arm 3 - Motivational interviewing (MI)
Participants receive up to 2 phone calls from trained genetics health coaches who provide information about genetic testing and use motivational interviewing to encourage participants to seek out clinical genetic testing.
|
At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants who complete clinical genetic testing at six months after randomization
Time Frame: 6 months after enrollment/randomization
|
The primary outcome is completion of genetic testing (yes/no) at 6 months after randomization by patient self-report.
|
6 months after enrollment/randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Barriers to genetic testing, for participants who completed genetic testing
Time Frame: 6 months and 12 months after enrollment/randomization
|
Participants who have completed genetic testing (before the 6- or 12-month time point for this survey) will be asked to respond to this 7-item, study-specific survey, developed by the investigators to assess the importance of specific barriers that were identified in a previous, observational study.
Each item is scored on a scale from 1-5 (1=not at all; 5=extremely).
The mean score for each question, across all participants who completed genetic testing, will be calculated in order to rank the barriers in importance.
A higher mean score indicates greater importance of that specific barrier.
|
6 months and 12 months after enrollment/randomization
|
Barriers to genetic testing, for participants who did not yet complete genetic testing
Time Frame: 6 months and 12 months after enrollment/randomization
|
Participants who have not yet completed genetic testing (before the 6- or 12-month time point for this survey) will be asked to respond to this 23-item, study-specific survey, developed by the investigators to assess the importance of specific barriers that were identified in a previous, observational study.
Each item is scored on a scale from 1-5 (1=not at all, 5=strongly agree).
The mean score for each question, across all participants who have not yet completed genetic testing, will be calculated in order to rank the barriers in importance.
A higher mean score indicates greater importance of that specific barrier.
|
6 months and 12 months after enrollment/randomization
|
Motivators of genetic testing, for participants who completed genetic testing
Time Frame: 6 months and 12 months after enrollment/randomization
|
Participants who have completed genetic testing (before the 6- or 12-month time point for this survey) will be asked to respond to this 5-item, study-specific survey, developed by the investigators to assess the importance of specific motivators for future testing.
Each item is scored on a scale from 1-5 (1=not at all; 5=extremely).
The mean score for each question, across all participants who completed genetic testing, will be calculated in order to rank the motivators in importance.
A higher mean score indicates greater importance of that specific motivator.
|
6 months and 12 months after enrollment/randomization
|
Motivators of genetic testing, for participants who did not yet complete genetic testing
Time Frame: 6 months and 12 months after enrollment/randomization
|
Participants who have not yet completed genetic testing (before the 6- or 12-month time point for this survey) will be asked to respond to this 5-item, study-specific survey, developed by the investigators to assess the importance of specific motivators for future testing.
Each item is scored on a scale from 1-5 (1=not at all, 5=strongly agree).
The mean score for each question, across all participants who have not yet completed genetic testing, will be calculated in order to rank the motivators in importance.
A higher mean score indicates greater importance of that specific motivator.
|
6 months and 12 months after enrollment/randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Elena Stoffel, MD, MPH, University of Michigan Rogel Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCC 2021.076
- U01CA232827 (U.S. NIH Grant/Contract)
- HUM00192898 (Other Identifier: University of Michigan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Publicly available genetic testing resources
-
University of WashingtonFace the FightNot yet recruitingStress | Distress, Emotional
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationCompleted
-
National Institute for Public Health and the Environment...Completed
-
Thomas Jefferson UniversityProstate Cancer FoundationActive, not recruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8United States
-
University of WashingtonNational Institute of Nursing Research (NINR)Recruiting
-
Montreal Heart InstituteCentre hospitalier de l'Université de Montréal (CHUM); Maisonneuve-Rosemont... and other collaboratorsCompletedAcute Coronary SyndromeCanada
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingDepression | Suicide, Attempted | Suicide | Major Depressive Disorder | Suicidal Ideas | MDD | Depression and Suicide | Depression in Adolescence | Depression, TeenUnited States
-
ClinLogic LLCMDGlobalRecruitingEarly Detection of CancerUnited States
-
UNICANCERInstitut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaboratorsRecruitingMutation | Hereditary Breast and Ovarian CancerFrance
-
Data Collection Analysis Business ManagementPAS Research ServicesUnknownEndometrial Cancer | Colon CancerUnited States